HOWL - Werewolf Therapeutics, Inc. Stock Price, Fair Value and News

2.72USD-0.02 (-0.73%)Market Closed

Market Summary

USD2.72-0.02

Market Closed

-0.73%

HOWL Stock Price

View Fullscreen

HOWL RSI Chart

HOWL Valuation

Market Cap

118.2M

Price/Earnings (Trailing)

-2.84

Price/Sales (Trailing)

6.27

Price/Free Cashflow

-3.05

HOWL Price/Sales (Trailing)

HOWL Profitability

Return on Equity

-35.36%

Return on Assets

-23.41%

Free Cashflow Yield

-32.76%

HOWL Fundamentals

HOWL Revenue

Revenue (TTM)

20.0M

Rev. Growth (Yr)

-79.64%

Rev. Growth (Qtr)

-74.85%

HOWL Earnings

Earnings (TTM)

-41.6M

Earnings Growth (Yr)

-35.14%

Earnings Growth (Qtr)

-34.91%

Breaking Down HOWL Revenue

Last 30 days

16.2%

Last 90 days

-59.7%

Trailing 12 Months

-0.4%

How does HOWL drawdown profile look like?

HOWL Financial Health

Current Ratio

6.71

HOWL Investor Care

Shares Dilution (1Y)

22.03%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	20.9M	24.8M	25.8M	20.0M
2022	4.2M	8.3M	12.3M	16.4M
2021	77.3K	91.5K	105.8K	120.0K
2020	0	0	0	63.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Daniel J. Hicklin Ph.D.
WEBSITE	https://werewolftx.com
INDUSTRY	Biotechnology
EMPLOYEES	48

Werewolf Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Werewolf Therapeutics, Inc.? What does HOWL stand for in stocks?

HOWL is the stock ticker symbol of Werewolf Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Werewolf Therapeutics, Inc. (HOWL)?

As of Fri Jul 26 2024, market cap of Werewolf Therapeutics, Inc. is 118.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOWL stock?

You can check HOWL's fair value in chart for subscribers.

Is Werewolf Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether HOWL is over valued or under valued. Whether Werewolf Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Werewolf Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOWL.

What is Werewolf Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, HOWL's PE ratio (Price to Earnings) is -2.84 and Price to Sales (PS) ratio is 6.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOWL PE ratio will change depending on the future growth rate expectations of investors.